Ulcerative Colitis Clinical Trial
— SLIRPSOfficial title:
Short Versus Long Interval to Ileostomy Reversal After Ileal Pouch Surgery for Ulcerative Colitis
Verified date | February 2022 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In patients with ulcerative or indeterminate colitis who undergo ileal pouch anal anastomosis and diverting loop ileostomy (IPAA) surgery* a short interval to loop ileostomy reversal will result in differences in complications and quality of life compared to a long interval to loop ileostomy reversal.
Status | Terminated |
Enrollment | 36 |
Est. completion date | March 31, 2021 |
Est. primary completion date | February 16, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility | Inclusion Criteria: - Signed informed consents. - Man or woman between 18 and 64 years of age. - Ulcerative colitis (UC) or indeterminate colitis (IC) diagnosed by routine clinical, radiographic, endoscopic, and pathological criteria. - Patient will be scheduled for non-emergent proctocolectomy or completion proctectomy with ileal j-pouch anal anastomosis (IPAA) and loop ileostomy (IPAA). - Clinical assessment of patient after IPAA surgery indicates that patient is suitable for early ileostomy reversal Exclusion Criteria: - Age < 18 or > 64 years - Colon or rectal cancer - Crohn's disease or suspected Crohn's disease - Prednisone dose > 20 mg per day (or equivalent other steroid dose) within 4 weeks of scheduled IPAA - Body mass index (BMI) equal to or greater than 40 kg/m2 - Hemodynamic instability (persistent pulse rate < 50 or > 120 bpm, systolic blood pressure < 90 or > 160 mm Hg, uncontrolled cardiac arrhythmia, or active vasopressor drug use) - Organ transplant recipient (e.g. Liver, Kidney, Pancreas) - Immunosuppression due to chemotherapy drug use or systemic disease. - Sepsis - Renal insufficiency (i.e. serum creatinine ? 2 mg/dl or need for dialysis) - Therapeutic anticoagulation (e.g. venous thromboembolic disease, prosthetic heart valve) - Blood Hemoglobin < 8 g/dl - Serum Albumin < 2.5 g/dl - Individualized decision by the surgeon to exclude the patient based on sound surgical judgment - Pregnant patients and female patients who do not satisfy the standard of care requirements of participating centers for an elective surgical procedure. - Clinical assessment of patient after IPAA surgery indicates that patient is not suitable for early ileostomy reversal - Participation in another clinical trial within the last 30 days, or simultaneous participation in another clinical trial - Well-founded doubt about the patient's cooperation. |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | University of Colorado Denver | Aurora | Colorado |
United States | Beth Israel | Boston | Massachusetts |
United States | Northwestern University Medical Center | Chicago | Illinois |
United States | University of Chicago | Chicago | Illinois |
United States | Cleveland Clinic | Cleveland | Ohio |
United States | Cedars Sinai | Los Angeles | California |
United States | Washington University | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comprehensive Complication Index at 6 months after randomization. | The CCI® calculator is an online tool to support the assessment of patients' overall morbidity. The Comprehensive Complication Index (CCI®) is based on the complication grading by Clavien-Dindo Classification and implements every occurred complication after an intervention. The overall morbidity is reflected on a scale from 0 (no complication) to 100 (death). | 6 months | |
Secondary | Total number of postoperative complications per patient | Post-operative complications. For example, surgical site infection, venous thromboembolism, lung or heart-related complications, etc.) | 6 months | |
Secondary | Percent of patients with complications | Percentage of patients with one or more postoperative complication such as surgical site infection, venous thromboembolism, lung or heart-related complications, etc. | 1-2 month intervals after randomization through 6 months". | |
Secondary | Total number of stoma related complications per patient | Examples: leakage, pain, retraction, prolapse, bleeding, etc. | 1-2 month intervals after randomization through 6 months | |
Secondary | Health-related quality of life | PROMIS questionnaire. This will be used to assess the study patient's overall health, quality of life, physical health, mental health, social activities, relationships, activities of daily living, emotional health, fatigue level, and pain. | Once, at 6 months after ostomy closure surgery | |
Secondary | IPAA functional outcomes | Daily stools, nightly stools, stool seepage, stool incontinence, anti-peristaltic medication use | Once, at 6 months after ostomy closure surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05702879 -
Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success
|
||
Not yet recruiting |
NCT05953402 -
A Study of Ozanimod in Pregnant Women With Ulcerative Colitis and Their Offspring
|
||
Recruiting |
NCT05316584 -
A Novel Remote Patient and Medication Monitoring Solution to Improve Adherence and PerSiStence With IBD Therapy
|
N/A | |
Recruiting |
NCT03950232 -
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
|
Phase 3 | |
Completed |
NCT03124121 -
Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels
|
Phase 4 | |
Not yet recruiting |
NCT06100289 -
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
|
Phase 3 | |
Withdrawn |
NCT04209556 -
A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis
|
Phase 2 | |
Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT04398550 -
SCD vs. Mediterranean Diet Therapy in Ulcerative Colitis
|
N/A | |
Recruiting |
NCT04314375 -
Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis
|
Phase 4 | |
Active, not recruiting |
NCT04857112 -
Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Active, not recruiting |
NCT04033445 -
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05428345 -
A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea
|
||
Active, not recruiting |
NCT06221995 -
Energy Expenditure in Patients With Ulcerative Colitis Undergoing Surgery
|
||
Recruiting |
NCT04767984 -
Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis
|
Phase 2 | |
Completed |
NCT02508012 -
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
|
N/A | |
Recruiting |
NCT06071312 -
FMT in Patients With Recurrent CDI and Ulcerative Colitis: Single Infusion Versus Sequential Approach
|
Phase 1/Phase 2 | |
Completed |
NCT03760003 -
Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative Colitis
|
Phase 2 | |
Not yet recruiting |
NCT05539625 -
Mini-MARVEL - Mitochondrial Antioxidant Therapy in Ulcerative Colitis
|
Phase 2 |